Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353668 | 1.00 | FKBP1A (0.32) | FKBP1ASMN1; SMN2POLB | |
| SCHEMBL6158610 | 0.82 | — | — | |
| SCHEMBL28380899 | 0.77 | — | — | |
| SCHEMBL14921057 | 0.76 | FKBP1A (0.33) | FKBP1ASMN1; SMN2 | |
| SCHEMBL24193468 | 0.72 | — | — | |
| SCHEMBL6474099 | 0.71 | — | — | |
| SCHEMBL6474094 | 0.71 | — | — | |
| SCHEMBL6474102 | 0.71 | — | — | |
| SCHEMBL17095031 | 0.70 | TSHR (0.36) | — | |
| SCHEMBL14861543 | 0.70 | CA1 (0.39) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-7482374-B2 | Pyrrolidine-2-ones as Factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| EP-1635817-B1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| US-20060167079-A1 | Pyrrolidine -2-ones as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1641752-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2006-04-05 | — | — | EP | disclosed |
| EP-1635817-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110435-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | TFPI, F2, F12 | FKBP1A 682/4885SMN1; SMN2 1777/4885POLB 1802/4885 |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | FKBP1A 369/4885SMN1; SMN2 1742/4885POLB 3476/4885 |
| US-20060167079-A1 | Pyrrolidine -2-ones as factor xa inhibitors | TFPI, F2, F11 | FKBP1A 440/4885SMN1; SMN2 4125/4885POLB 1340/4885 |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | FKBP1A 348/4885SMN1; SMN2 3081/4885POLB 3721/4885 |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | SERPINE1, PLAT, SERPINC1 | FKBP1A 867/4885SMN1; SMN2 2502/4885POLB 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.